Description
As Europe's largest academic department in the field, the University of Oxford’s Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS) we deliver a multidisciplinary programme of research and education, supported by a research grant portfolio exceeding £230 million. We investigate the underlying causes of musculoskeletal and inflammatory conditions to provide outstanding, innovative care that enhances quality of life worldwide. Our expanding community comprises over 500 staff members, approximately 100 postgraduate students, more than 30 professors, as well as university lecturers and senior researchers. Our expert team brings specialised knowledge across diverse areas, including orthopaedic surgery, inflammation, immunology, rheumatology, medical statistics, epidemiology, health economics, data science, and clinical trials. Our strategic location alongside NHS services at Oxford's Nuffield Orthopaedic Centre creates a distinctive advantage, enabling laboratory researchers and clinicians to work side by side. This proximity significantly strengthens our research capabilities by providing researchers with direct patient access and fostering essential collaboration between clinicians and scientists—a critical foundation for successful translational research.
Role with PROBE
The Vincent team (Prof Tonia Vincent and Dr Thomas Perry) will study the molecular pathogenesis of OA and will help to refine disease targets arising from multiomic data by aligning them with published mechanistic studies. They will also contribute their expertise in proteomic analysis of the synovial fluid in OA through their STEpUP OA cohort. The Health Economics and Outcomes Research group led by Associate Professor Rafael Pinedo-Villanueva will develop a framework for economic models that estimate the long-term effects of novel osteoarthritis therapies on quality of life and on costs leveraging real world evidence through a federated approach. They will be working together with the various Councils contributing the perspective of patients, healthcare professionals, regulatory bodies, and health technology assessment agencies into this framework.
